Intervention(s) and comparator(s)	Participants included in analysis (N)	Deaths (N)	Deaths (%)	Participants with adverse events (N)	Participants with adverse events (%)	Participants with severe/serious adverse events (N)	Participants with severe/serious adverse events (%)
Avilés 1999	I: metformin	22	‐	‐	3	14	‐	‐
	C: placebo	23	‐	‐	‐	‐	‐	‐
Barnett 2013	I: saxagliptin	95	1	1.1	61	64.2	9	9.5
	C: placebo	46	0	0	32	69.6	3	6.5
Casner 1988	I: glibenclamide	31	‐		‐	‐	‐	0
	C: placebo	33	‐		‐	‐	‐	0
Chiasson 1994	I: acarbose	35	‐	‐	1	2.4	0	0
	C: placebo	44	‐	‐	3	2.9	0	0
Coniff 1995	I: acarbose	103	‐	‐	78	76	0	0
	C: placebo	104	‐	‐	36	35	0	0
Feinglos 1998	I: glipizide		‐			‐		‐
	C: placebo							‐
	all:	29	‐	‐	69 episodes of hypoglycaemia	‐	1	‐
Fonseca 2007	I: vildagliptin	144	1	0.7	‐	81.3	‐	8.3
	C: placebo	152	1	0.7	‐	82.9	‐	9.2
Fritsche 2000	I: metformin	‐	‐	‐	0	0	0	0
	C: placebo	‐	‐	‐	0	0	0	0
	all:	13	‐	‐	0	0	0	0
Giugliano 1993	I: metformin	27	‐	‐	2	7.4	0	0
	C: placebo	23	‐	‐	‐	‐	‐	‐
Groop 1985	I: glibenclamide	‐	‐	‐	‐	‐	‐	‐
	C: placebo	‐	‐	‐	‐	‐	‐	‐
	all:	13	‐	‐	‐	‐	‐	‐
Hermann 2001	I: metformin	16	‐	‐	9	‐	‐	‐
	C: placebo	19	‐	‐	6	‐	‐	‐
Hong 2012	I: sitagliptin	61	‐	‐	‐	34.4	1	‐
	C: insulin increase	63	‐	‐	‐	36.5	4	‐
Hirsch 1999	I: metformin	25	‐	‐	3	12	0	0
	C: placebo	25	‐	‐	0	‐	0	0
Kitabchi 1987	I: tolazamide		‐	‐	‐	‐	‐	‐
	C: NPH alone		‐	‐	‐	‐	‐	‐
	all:	12	‐	‐	‐	‐	‐	‐
Krawczyk 2005	I: metformin	20	‐	‐	‐	‐	‐	‐
	C: insulin alone	20	‐	‐	‐	‐	‐	‐
Kyllastinen 1985	I: glibenclamide	‐	‐	‐	‐	‐	‐	‐
	C: placebo	‐	‐	‐	‐	‐	‐	‐
	all:	9	‐		‐	‐	‐	‐
Lewitt 1989	I: glibenclamide		‐	‐	‐	‐	‐	‐
	C: placebo		‐	‐	‐	‐	‐	‐
	all:	31	‐	‐	‐	‐	‐	‐
Lindström 1999	I: glibenclamide	‐	‐	‐	‐	‐	‐	‐
	C: placebo	‐	‐	‐	‐	‐	‐	‐
	all:	15	‐	‐	‐	‐	‐	‐
Longnecker 1986	I: tolazamide	‐	‐	‐	0	0	0	0
	C: placebo	‐	‐	‐	0	0	0	0
	all:	11	‐	‐	0	0	0	0
Mattoo 2005	I: pioglitazone	128	0	0	109	76.8	‐	‐
	C: placebo	135	1	0.7	98	66.7	‐	‐
Mauerhoff 1986	I: glibenclamide	11	0	0	107 episodes	‐	‐	‐
	C: placebo	11	0	0	25 episodes	‐	‐	‐
Mezitis 1992	I: glibenclamide	10	‐	‐	‐	‐	‐	‐
	C: placebo	10	‐	‐	‐	‐	‐	‐
	all:	20	‐	‐	‐	‐	‐	‐
Mudaliar 2010	I: pioglitazone	12	‐	‐	‐	‐	‐	‐
	C: placebo	13	‐	‐	‐	‐	‐	‐
Nemoto 2011	I: miglitol	107	‐	‐	122 episodes	78.5	‐	‐
	C: placebo	100	‐	‐	91 episodes	76	‐	‐
Osei 1984	I: glibenclamide	6	‐	‐	‐	‐	‐	‐
	C: placebo	11	‐	‐	‐	‐	‐	‐
Quartraro 1986	I: gliclazide	15	0	0	‐	‐	‐	‐
	C: insulin alone	15	0	0	‐	‐	‐	‐
Reich 1987	I: glibenclamide	10	1	10	3 (5 episodes)	30	‐	‐
	C: placebo	10	0	0	10 episodes	‐	‐	‐
Relimpio 1998	I: metformin	24	‐	‐	‐	‐	‐	‐
	C: insulin dose increase	23	‐	‐	‐	‐	‐	‐
Robinson 1998	I: metformin	‐	‐	‐	‐	‐	0	0
	C: placebo	‐	‐	‐	‐	‐	0	0
	all:	19	‐	‐	‐	‐	0	0
Rosenstock 2002	I1: pioglitazone 15 mg	191	‐	‐	‐	78.4	‐	‐
	I2: pioglitazone 30 mg	188	‐	‐	‐		‐	‐
	C: placebo	187	‐	‐	‐	74.3	‐
Schade 1987	I: glibenclamide	16			6	37.5	0	0
	C: placebo	16			1	6.3	0	0
Schiel 2007	I1: glimepiride	17	‐	‐	‐	59	0	0
	I2: glimepiride + metformin	18	‐	‐	‐	72	0	0
	C: insulin	17	‐	‐	‐	77	0	0
Simpson 1990	I: glipizide	9	‐	‐	4	44.4	‐	‐
	C: placebo	10	‐	‐	0	0	‐	‐
Stenman 1988	I: glibenclamide	15	0	0	13	86.7	0	0
	C: placebo	15	0	0	8	53.3	0	0
Strowig 2002	I1: metformin	27	0	0	‐	‐	2	6.7
	I2: troglitazone	30	0	0	‐	‐	0	0
	C: insulin	31	0	0	‐	‐	1	3.2
Wulffelé 2002	I: metformin	171	1	0.6	1 episode per participant per month: 31 2 episodes per participant per month: 12 3 episodes per participant per month: 9 ≥ 4 episodes per participant per month: 11	1 episode per participant per month: 18 2 episodes per participant per month: 7 3 episodes per participant per month: 5 ≥ 4 episodes per participant per month: 6	8 episodes	‐
	C: placebo	182	0	0	1 episode per participant per month: 30 2 episodes per participant per month: 11 3 episodes per participant per month: 11 ≥ 4 episodes per participant per month: 7	1 episode per participant per month: 16 2 episodes per participant per month: 6 3 episodes per participant per month: 6 ≥ 4 episodes per participant per month: 4	4 episodes
Yilmaz 2007	I1: acarbose	15	0	0	3	20	0	0
	I2: metformin	17	0	0	5	29.4	0	0
	I3: rosiglitazone	15	0	0	3	20	0	0
	C: insulin alone	19	0	0	3	15.8	0	0
‐ denotes not reported C: comparator; I: intervention; NPH: Neutral Protamine Hagedorn